bioAffinity Technologies Reports Strong Growth in Lung Test Sales

bioAffinity Technologies, Inc. ( (BIAF) ) has released its Q2 earnings. Here is a breakdown of the information bioAffinity Technologies, Inc. presented to its investors.

bioAffinity Technologies, Inc. is a biotechnology company specializing in noninvasive diagnostics for early-stage lung cancer and other lung diseases, with a focus on developing innovative cancer treatments.

In the second quarter of 2025, bioAffinity Technologies reported a significant increase in revenue from its CyPath® Lung test, which rose by 62% year-over-year for the first half of the year. The company also achieved record monthly sales in June and July, underscoring the growing adoption of its diagnostic solutions.

Key financial highlights include a strategic shift away from unprofitable pathology services, leading to a decrease in overall revenue to $1.3 million for the quarter. Despite this, the company successfully raised $3.25 million through a public offering and reduced operating expenses by 16% compared to the previous year. The appointment of Dr. Gordon Downie as Chief Medical Officer and the expansion of its intellectual property portfolio further strengthen its strategic position.

Looking ahead, bioAffinity Technologies aims to expand its market presence and enhance operational efficiency. The company remains committed to advancing its diagnostic and therapeutic platforms, with a focus on improving patient outcomes and delivering value to shareholders.